サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609657

日本の医薬品原薬市場レポート：医薬品タイプ、メーカータイプ、合成タイプ、治療用途、地域別、2025年～2033年

Japan Active Pharmaceutical Ingredients Market Report by Drug Type, Type of Manufacturer, Type of Synthesis, Therapeutic Application, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 118 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
日本の医薬品原薬市場レポート：医薬品タイプ、メーカータイプ、合成タイプ、治療用途、地域別、2025年～2033年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 118 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の医薬品原薬市場規模は2024年に279億米ドルに達しました。今後、IMARC Groupは、2033年には432億米ドルに達し、2025年から2033年にかけて5%の成長率（CAGR）を示すと予測しています。バイオシミラーやジェネリック医薬品へのニーズの高まりと臨床試験数の増加が、主に市場成長の原動力となっています。

本レポートで扱う主な質問

  • 日本の医薬品原薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が日本の医薬品原薬市場に与えた影響は？
  • 日本の医薬品原薬市場の薬剤タイプ別区分は？
  • 日本の医薬品原薬市場のメーカータイプ別区分は？
  • 日本の医薬品原薬市場の合成タイプ別構成比は？
  • 治療用途別の日本の医薬品原薬市場の内訳は？
  • 日本の医薬品原薬市場のバリューチェーンにおける様々な段階とは？
  • 日本の医薬品原薬市場の主な促進要因と課題は何か？
  • 日本の医薬品原薬市場の構造と主要プレーヤーは？
  • 日本の医薬品原薬市場の競合状況は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の医薬品原薬（API）市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本の医薬品原薬（API）市場情勢

  • 過去および現在の市場動向（2019年～2024年）
  • 市場予測（2025-2033）

第6章 日本の医薬品原薬（API）市場：医薬品タイプ内訳

  • イノベーティブ医薬品原薬（API）
  • ジェネリック医薬品原薬（API）

第7章 日本の医薬品原薬（API）市場：メーカータイプ別内訳

  • キャプティブメーカー
  • マーチャント APIメーカー

第8章 日本の医薬品原薬（API）市場：合成タイプ別内訳

  • 合成医薬品原薬（API）
  • バイオテクノロジー医薬品原薬（API）

第9章 日本の医薬品原薬（API）市場：治療用途別内訳

  • 腫瘍学
  • 心臓血管と呼吸器
  • 糖尿病
  • 中枢神経系疾患
  • 神経疾患
  • その他

第10章 日本の医薬品原薬（API）市場：競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第11章 主要企業のプロファイル

第12章 日本の医薬品原薬（API）市場：業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第13章 付録

目次
Product Code: SR112024A16298

Japan active pharmaceutical ingredients (API) market size reached USD 27.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 43.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5% during 2025-2033. The increasing need for biosimilars and generic drugs, coupled with the growing number of clinical trials, is primarily driving the market growth.

Active pharmaceutical ingredients (APIs) are essential components of medications, ensuring they deliver the desired healing outcomes. These biologically active compounds are vital in treating and managing symptoms of numerous health issues. They are crafted through intricate chemical and biological methodologies, with their purity, strength, and consistency being critical for their medicinal efficacy. APIs enable specific treatments for a wide range of illnesses, allowing pharmaceutical companies to create drugs tailored to specific diseases and populations. They are incorporated in various drug formats, such as pills, capsules, creams, or injections, each with unique manufacturing needs. In line with this, active pharmaceutical ingredients contribute to the progression of drug delivery techniques, enhancing the efficient and safe dispersion of drugs within the human body.

Japan Active Pharmaceutical Ingredients (API) Market Trends:

The active pharmaceutical ingredients market in Japan is witnessing substantial growth, driven predominantly by the exponential progression in its pharmaceutical domain. As Japan grapples with a rising prevalence of various chronic ailments, there's a heightened demand for APIs, mirroring emerging trends. A notable factor propelling this market trajectory in Japan is the intensive research and development endeavors by its pharmaceutical giants. Additionally, their quest to launch enhanced product iterations, especially high-potency active pharmaceutical ingredients, paints an optimistic picture for the nation's API market. Besides this, the unprecedented strides taken by the Japanese pharmaceutical sector during global health crises further amplify this market's momentum. Concurrently, Japan, being a hotspot of technological evolution, is experiencing breakthroughs in biotechnology and life sciences, factors that are auspiciously shaping its API landscape. An augmented count of research institutions and the uptick in clinical explorations signify the growth potential. Compounded by the rapid urban sprawl, Japan's burgeoning elderly demographic, and substantial investments by both governmental and private entities towards refining the healthcare infrastructure, it's evident that Japan's active pharmaceutical ingredients market is poised for sustained growth in the foreseeable future.

Japan Active Pharmaceutical Ingredients (API) Market Segmentation:

Drug Type Insights:

  • Innovative Active Pharmaceutical Ingredients (API)
  • Generic Active Pharmaceutical Ingredients (API)

Type of Manufacturer Insights:

  • Captive Manufacturers
  • Merchant API Manufacturers
  • Innovative Merchant API Manufacturers
  • Generic Merchant API Manufacturers

Type of Synthesis Insights:

  • Synthetic Active Pharmaceutical Ingredients (API)
  • Type
  • Innovative Synthetic APIs
  • Generic Synthetic APIs
  • Biotech Active Pharmaceutical Ingredients (API)
  • Type
  • Innovative Biotech APIs
  • Biosimilars
  • Product
  • Monoclonal Antibodies
  • Vaccines
  • Cytokines
  • Fusion Proteins
  • Therapeutic Enzymes
  • Blood Factors
  • Expression System
  • Mammalian Expression Systems
  • Microbial Expression Systems
  • Yeast Expression Systems
  • Transgenic Animal Systems
  • Others

Therapeutic Application Insights:

  • Oncology
  • Cardiovascular and Respiratory
  • Diabetes
  • Central Nervous System Disorders
  • Neurological Disorders
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan active pharmaceutical ingredients (API) market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan active pharmaceutical ingredients (API) market?
  • What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of drug type?
  • What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of manufacturer?
  • What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of type of synthesis?
  • What is the breakup of the Japan active pharmaceutical ingredients (API) market on the basis of therapeutic application?
  • What are the various stages in the value chain of the Japan active pharmaceutical ingredients (API) market?
  • What are the key driving factors and challenges in the Japan active pharmaceutical ingredients (API)?
  • What is the structure of the Japan active pharmaceutical ingredients (API) market and who are the key players?
  • What is the degree of competition in the Japan active pharmaceutical ingredients (API) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Active Pharmaceutical Ingredients (API) Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Active Pharmaceutical Ingredients (API) Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Drug Type

  • 6.1 Innovative Active Pharmaceutical Ingredients (API)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Generic Active Pharmaceutical Ingredients (API)
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)

7 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Manufacturer

  • 7.1 Captive Manufacturers
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Merchant API Manufacturers
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Segmentation
      • 7.2.3.1 Innovative Merchant API Manufacturers
      • 7.2.3.2 Generic Merchant API Manufacturers
    • 7.2.4 Market Forecast (2025-2033)

8 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Type of Synthesis

  • 8.1 Synthetic Active Pharmaceutical Ingredients (API)
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Segmentation
      • 8.1.3.1 Type
        • 8.1.3.1.1 Innovative Synthetic APIs
        • 8.1.3.1.2 Generic Synthetic APIs
    • 8.1.4 Market Forecast (2025-2033)
  • 8.2 Biotech Active Pharmaceutical Ingredients (API)
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Segmentation
      • 8.2.3.1 Type
        • 8.2.3.1.1 Innovative Biotech APIs
        • 8.2.3.1.2 Biosimilars
      • 8.2.3.2 Product
        • 8.2.3.2.1 Monoclonal Antibodies
        • 8.2.3.2.2 Vaccines
        • 8.2.3.2.3 Cytokines
        • 8.2.3.2.4 Fusion Proteins
        • 8.2.3.2.5 Therapeutic Enzymes
        • 8.2.3.2.6 Blood Factors
      • 8.2.3.3 Expression System
        • 8.2.3.3.1 Mammalian Expression Systems
        • 8.2.3.3.2 Microbial Expression Systems
        • 8.2.3.3.3 Yeast Expression Systems
        • 8.2.3.3.4 Transgenic Animal Systems
        • 8.2.3.3.5 Others
    • 8.2.4 Market Forecast (2025-2033)

9 Japan Active Pharmaceutical Ingredients (API) Market - Breakup by Therapeutic Application

  • 9.1 Oncology
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Forecast (2025-2033)
  • 9.2 Cardiovascular and Respiratory
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Forecast (2025-2033)
  • 9.3 Diabetes
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2019-2024)
    • 9.3.3 Market Forecast (2025-2033)
  • 9.4 Central Nervous System Disorders
    • 9.4.1 Overview
    • 9.4.2 Historical and Current Market Trends (2019-2024)
    • 9.4.3 Market Forecast (2025-2033)
  • 9.5 Neurological Disorders
    • 9.5.1 Overview
    • 9.5.2 Historical and Current Market Trends (2019-2024)
    • 9.5.3 Market Forecast (2025-2033)
  • 9.6 Others
    • 9.6.1 Historical and Current Market Trends (2019-2024)
    • 9.6.2 Market Forecast (2025-2033)

10 Japan Active Pharmaceutical Ingredients (API) Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Active Pharmaceutical Ingredients (API) Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix